Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Expert Rev Vaccines ; 16(3): 273-287, 2017 03.
Artículo en Inglés | MEDLINE | ID: mdl-27809689

RESUMEN

INTRODUCTION: Rabies is a worldwide zoonotic viral disease with no specific treatment once symptoms occur; manifest disease is almost always fatal. WHO recommendations for exposed individuals include immediate attention to the wound and use of rabies immunoglobulin and/or vaccine for post-exposure prophylaxis (PEP). Here, we provide an overview of the clinical experience with a highly purified preparation of F(ab')2 fragments from equine rabies immunoglobulin (F(ab')2 pERIG; FavirabTM) in rabies PEP. Areas covered: Our review comprises a retrospective analysis of adverse event reports in the Sanofi Pasteur global pharmacovigilance database for F(ab')2 pERIG, including adverse event reports from eight Sanofi Pasteur-sponsored clinical trials and post-market surveillance data collected between 1995 and 2014. The general safety profile of F(ab')2 pERIG is discussed, as are the occurrence of rare anaphylactic reactions, and suspected intervention failure. Expert commentary: Over 20 years of clinical development and post-licensure experience has established the safety and effectiveness of F(ab')2 pERIG (FavirabTM) in rabies PEP.


Asunto(s)
Fragmentos Fab de Inmunoglobulinas/administración & dosificación , Fragmentos Fab de Inmunoglobulinas/efectos adversos , Vacunas Antirrábicas/administración & dosificación , Vacunas Antirrábicas/efectos adversos , Rabia/prevención & control , Anafilaxia/etiología , Animales , Humanos , Fragmentos Fab de Inmunoglobulinas/inmunología , Farmacovigilancia , Profilaxis Posexposición , Vigilancia de Productos Comercializados , Vacunas Antirrábicas/inmunología , Estudios Retrospectivos
2.
Cornea ; 29(5): 541-9, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-20418717

RESUMEN

PURPOSE: We evaluated (1) 4 multipurpose lens care solutions and 3 contact lenses (soft and rigid) for cytotoxicity according to ISO 10993-5 standard (medical device biocompatibility) and (2) the protective effects of a marine cationic solution and hyaluronic acid. METHODS: Low water soft lens, high water soft lens, and rigid lens were laid on a conjunctival cell line after being soaked in multipurpose solution (Optifree Express, Renu, Solocare Aqua, or Menicare Plus). Cell morphology was microscopically observed, and cell viability was evaluated using the neutral red test. Apoptosis was assessed after direct contact of multipurpose solutions (MPS) with conjunctival cells using fluorescence microscopy and flow cytometry. The ability of a controlled ionization marine solution and hyaluronic acid to prevent multipurpose solution's cytotoxicity was finally evaluated. RESULTS: Contact lenses soaked in the MPS induced cell morphology alterations and loss of cell viability. Rinsing the lens with the marine solution improved cell viability and preincubating cells with hyaluronic acid inhibited apoptosis. CONCLUSIONS: MPS can be damaging for the ocular surface cells. We proposed to rinse the lens with a marine solution before insertion of the lens on the cornea to wash away the multipurpose solution and to use hyaluronic acid to protect the ocular surface cells against apoptosis induced by MPS.


Asunto(s)
Apoptosis/efectos de los fármacos , Conjuntiva/efectos de los fármacos , Soluciones para Lentes de Contacto/toxicidad , Lentes de Contacto , Animales , Línea Celular , Supervivencia Celular/efectos de los fármacos , Cromatina/efectos de los fármacos , Conjuntiva/patología , Fragmentación del ADN/efectos de los fármacos , Citometría de Flujo , Humanos , Ácido Hialurónico/toxicidad , Masculino , Microscopía Fluorescente , Conejos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA